Literature DB >> 4146764

Pharmacological analysis of the acute inflammatory process induced in the rat's paw by local injection of carrageenin and by heating.

J Garcia Leme, L Hamamura, M P Leite, M Rocha e Silva.   

Abstract

1. Local injection of carrageenin in the rat's paw produced oedema and leakage of dye which had been administered previously by the intravenous route. A net dissociation between both parameters was observed: while oedema developed slowly, maximal intensity being attained after 4-5 h, dye-leakage was maximum after 1 hour.2. Anti-inflammatory drugs such as acetylsalicylic acid and indomethacin were effective in reducing oedema and dye-leakage when given before the injection of carrageenin, but much less effective when given 30 or 60 min after carrageenin. Hexadimethrine bromide was effective in reducing dye-leakage also when given 1 h after the injection of carrageenin.3. Combined administration of benadryl and methysergide, before the injection of carrageenin caused only a slight reduction in oedema and dye-leakage.4. When the paws were heated (55 degrees C for 30 s) as a noxious stimulus the dissociation between maximal oedema and maximal dye-leakage was not observed, both phenomena running parallel. Pre-treatment of the animals with indomethacin did not afford any protection.5. These results suggest that the inflammatory reaction to mild stimuli (carrageenin in our experiments) develops through different phases: initially the increased vascular permeability involves extravasation of plasma proteins and that phase is followed by an increased permeability mainly to water. Stronger stimuli (heating in our experiments) produce an overlapping of both phases, probably by inflicting severe damage to the vascular bed of the affected area.6. The anti-inflammatory drugs employed affected chiefly the initial phase of the response.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4146764      PMCID: PMC1776102          DOI: 10.1111/j.1476-5381.1973.tb08225.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  KININ-FORMING ACTIVITY AND HISTAMINE IN LYMPH AFTER TISSUE INJURY.

Authors:  H EDERY; G P LEWIS
Journal:  J Physiol       Date:  1963-12       Impact factor: 5.182

2.  ON THE ANTI-INFLAMMATORY ACTIVITY OF PROTAMINE SULPHATE AND OF HEXADIMETHRINE BROMIDE, INHIBITORS OF PLASMA KININ FORMATION.

Authors:  D N KELLETT
Journal:  Br J Pharmacol Chemother       Date:  1965-06

3.  Anti-heparin agents as inhibitors of plasma kinin formation.

Authors:  D A ARMSTRONG; J W STEWART
Journal:  Nature       Date:  1962-05-19       Impact factor: 49.962

4.  Early and delayed oedema and increase in capillary permeability after burns of the skin.

Authors:  S SEVITT
Journal:  J Pathol Bacteriol       Date:  1958-01

5.  Rapid foot volume measurements on unanesthetized rats, and the question of a phenylbutazone effect on anaphylactoid edema.

Authors:  C V WINDER; J WAX; M A BEEN
Journal:  Arch Int Pharmacodyn Ther       Date:  1957-10-01

6.  Effect of anti-proteases and hexadimethrine bromide on the release of a bradykinin-like substance during heating (46 degrees C) of rat paws.

Authors:  J Garcia Leme; L Hamamura; M Rocha e Silva
Journal:  Br J Pharmacol       Date:  1970-10       Impact factor: 8.739

7.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

Authors:  J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

8.  Indomethacin and aspirin abolish prostaglandin release from the spleen.

Authors:  S H Ferreira; S Moncada; J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

9.  Mediators of the inflammation induced in the rat paw by carrageenin.

Authors:  P Crunkhorn; S C Meacock
Journal:  Br J Pharmacol       Date:  1971-07       Impact factor: 8.739

  9 in total
  30 in total

1.  Cell-mediated immune response to unrelated proteins and unspecific inflammation blocked by orally tolerated proteins.

Authors:  Gustavo C Ramos; Claudiney M Rodrigues; Geraldo M Azevedo; Vanessa Pinho; Cláudia R Carvalho; Nelson M Vaz
Journal:  Immunology       Date:  2008-08-28       Impact factor: 7.397

2.  Enhancement of the responses of ascending tract cells in the cat spinal cord by acute inflammation of the knee joint.

Authors:  H G Schaible; R F Schmidt; W D Willis
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

3.  Impact of diabetes against the future risk of developing gout.

Authors:  García Rodríguez; Lucia Cea Soriano; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2010-06-22       Impact factor: 19.103

4.  Acute inflammatory responses in rats with protein-calorie malnutrition.

Authors:  M R Leme-Brasil; E F Collares; S B Verissimo De Mello; J Garcia-Leme
Journal:  Agents Actions       Date:  1980-11

5.  Chronobiological study of plasma exudation in carrageenan-paw oedema in the rat.

Authors:  G Labrecque; F M Doré; P M Bélanger; V Carter
Journal:  Agents Actions       Date:  1984-06

6.  Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom.

Authors:  H A Trebien; J B Calixto
Journal:  Agents Actions       Date:  1989-03

7.  Therapeutic reduction of ongoing carrageenin-induced inflammation by lipoxygenase, but not cyclooxygenase inhibitors.

Authors:  M P Holsapple; G K Yim
Journal:  Inflammation       Date:  1984-09       Impact factor: 4.092

8.  Evaluation of the analgesic and anti-inflammatory activities of Curcuma mangga Val and Zijp rhizomes.

Authors:  Peerati Ruangsang; Supinya Tewtrakul; Wantana Reanmongkol
Journal:  J Nat Med       Date:  2009-10-15       Impact factor: 2.343

9.  Relationship between oedema and plasma exudation in rat paw carrageenin inflammation.

Authors:  M T Zanin; S H Ferreira
Journal:  Agents Actions       Date:  1978-12

10.  Antinociceptive and anti-inflammatory effects of ethanolic extracts of Glycine max (L.) Merr and Rhynchosia nulubilis seeds.

Authors:  Joo Hyuk Yim; Ok-Hwan Lee; Ung-Kyu Choi; Young-Chan Kim
Journal:  Int J Mol Sci       Date:  2009-11-04       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.